SPH7854

Phase 1Small molecule

SShanghai Pharmaceuticals Holding Co., Ltd

SPH7854 is one of 52 small molecule programs targeting Inflammatory Bowel Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseaseRecruiting

Inflammatory Bowel DiseasePhase 1

Recruiting

Competition

Competitive Landscape

62 competitors in Inflammatory Bowel Disease

#DrugCompanyPhaseTrials

Remicade

Johnson & Johnson

Approved

17 2

Skyrizi

AbbVie

Approved

3 3

Dificlir

Merck & Co.

Approved

1 4

Humira

RRanbaxy Laboratories Limited

Approved

7 5

Mounjaro

Elavil

Calciferol

Vancocin

HHikma Pharmaceuticals LLC

Approved

1 9

Spravato

WWim Janssens

Approved

1 10

Aplenzin

GGlaxo Dba Glaxosmithkline

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

A Clinical Study of SPH7854 Granules in Healthy Subjects.

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT06483373·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SPH7854. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPH7854 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPH7854. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceuticals Holding Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai Pharmaceuticals Holding Co., Ltd

SPH7854

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News